oasis-1 oral semaglutide 50 mg obesity nejm 2023 for the treatment of obesity: a retrospective real-world study oral semaglutide 50 mg oasis

This provides new biomarkers and therapeutic targets for Sjgrens syndrome

Johanna Olson-Kennedy Person Yep

As many have noted the continuation of the perioperative effects GLP-1 RAs have on patients, even after seemingly adequate time since discontinuation in addition to following strict fasting guidelines, there have expectedly been new estimates on appropriate discontinuation strategies

received a NHMRC Senior Principal Research Fellowship (grant ID: 1154434), a NHMRC Leadership grant (ID: 2025694), and an ARC Discovery Project grant (DP210101504)

How to Speed Up the Process: Provide as much supporting documentation as possible on your first submission